Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
NCT00845182 on ClinicalTrials.gov · last registry update 2018-01-18
Finished July 2010, after enrolling 43 people. Primary outcome, as filed: Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight. exenatide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor type
- Other
- Enrollment
- 43
- Started
- 2007-06
- Primary completion
- 2010-07 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight
Conditions studied
Type 2 Diabetes · Healthy · Impaired Glucose Tolerance
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.